Abstract
Aims: To examine the relative efficacy of live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) as a function of time post-vaccination from three large randomized studies that compared the efficacy of LAIV and TIV in children. LAIV is approved for use in eligible individuals 2 to 49 years of age in the U.S., Israel, Hong Kong, Macau, and South Korea.
Methods: Relative efficacy of LAIV vs. TIV against culture-confirmed influenza was calculated by timeinterval (0-4 and >4-8 months postvaccination) for matched strains, the studies' primary endpoint. Match for B viruses in Study 1 was based on genetic sequence as serology was less reliable.
Results: In each study, LAIV recipients had less influenza than TIV recipients in both time intervals and the relative efficacy of LAIV vs. TIV increased from 0-4 months to 4-8 months.
Conclusions: For matched strains, the available data suggest that the relative efficacy of LAIV vs. TIV in children increases over time. Further research is needed to confirm these findings and to characterize the duration of protection provided by TIV in children. Sponsored by MedImmune.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Belshe, R., Ambrose, C., Wu, X. et al. 537 Relative Efficacy of Live Attenuated and Inactivated Influenza Vaccines in Children as a Function of Time Postvaccination. Pediatr Res 68 (Suppl 1), 274–275 (2010). https://doi.org/10.1203/00006450-201011001-00537
Issue Date:
DOI: https://doi.org/10.1203/00006450-201011001-00537